Oruka Therapeutics designs long-acting monoclonal antibodies for plaque psoriasis, psoriatic arthritis and related inflammatory skin diseases. Its programs build on validated cytokine pathways with the goal of high rates of complete skin clearance and dosing as infrequent as once or twice a year. Lead assets originated from antibody discovery work at Paragon Therapeutics. The company remains clinical-stage, with no commercial products yet.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -24.6 | — |
| Q3 2025 | 0 | — | -30.3 | — |
| Q4 2025 | 0 | — | -29.6 | — |
| Q1 2026 | 0 | — | -31.8 | — |
| Q2 2026 | 0 | — | -41.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: CRISPR Therapeutics AG (CRSP), Regencell Bioscience Holdings Limited (RGC), Icahn Enterprises L.P. (IEP), Insight Enterprises, Inc. (NSIT), Construction Partners, Inc. (ROAD), Dave Inc. (DAVE)